Vaccine sales power Pfizer through first quarter
LINDA A. JOHNSON, AP Medical Writer
May 4, 2021
FacebookTwitterEmail 5
1of5FILE - In this April 14, 2021 file photo, a Northwell Health nurse injects Local 28 Sheet Metal Worker Demetrius Buttelman with the first dose of the Pfizer vaccine during a news conference, at the Belmont Park in Elmont, N.Y. The state recorded 43,000 new cases in the week that ended Saturday, April 17, 2021. That s the lowest number in a seven-day period since Thanksgiving.Mary Altaffer/APShow MoreShow Less
2of5Gov. Andrew Cuomo embraces Radhames Rodriguez, President of United Bodegas of America, after Rodriguez received a Pfizer COVID-19 vaccination shot at an event to announce five new walk-in pop-up COVID-19 vaccination sites for New York Bodega, grocery store and supermarket workers in the Harlem section of New York on Friday, April 23, 2021. (Mike Segar/Pool Photo via AP)Mike Segar/APShow MoreShow Less
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration approved its supplemental New Drug Application or sNDA for Lorbrena or lorlatinib, expanding the indication
Mar 4, 2021 10:54am
The FDA has expanded Pfizer s Lorbrena approval to include front-line ALK-positive non-small cell lung cancer.
Pfizer’s Lorbrena has finally broken into front-line non-small cell lung cancer, where Novartis, Roche and Takeda are already jockeying for a niche market.
The FDA expanded Lorbrena’s use into newly diagnosed patients with ALK-positive NSCLC, Pfizer said Wednesday. With that front-line nod, the agency converted Lorbrena s conditional green light for previously treated cases into a full approval.
How does Pfizer expect to compete in such a crowded field? As a third-generation ALK inhibitor, Lorbrena has arguably the best efficacy data in head-to-head tests against its predecessor, Xalkori.